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Abstract
 
The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in particular, those which raise insulin
levels independently of blood glucose, such as sulphonylureas (SUs) and exogenous insulin. The risk of hypoglycaemia is
increased in older patients, those with longer diabetes duration, lesser insulin reserve and perhaps in the drive for strict
glycaemic control. Differing definitions, data collection methods, drug type/regimen and patient populations make com-
paring rates of hypoglycaemia difficult. It is clear that patients taking insulin have the highest rates of self-reported severe
hypoglycaemia (25% in patients who have been taking insulin for 
 
>
 
 5 years). SUs are associated with significantly lower
rates of severe hypoglycaemia. However, large numbers of patients take SUs in the UK, and it is estimated that each year
 
>
 
 5000 patients will experience a severe event caused by their SU therapy which will require emergency intervention.
Hypoglycaemia has substantial clinical impact, in terms of mortality, morbidity and quality of life. The cost implications
of severe episodes—both direct hospital costs and indirect costs—are considerable: it is estimated that each hospital admission
for severe hypoglycaemia costs around £1000. Hypoglycaemia and fear of hypoglycaemia limit the ability of current diabetes
medications to achieve and maintain optimal levels of glycaemic control. Newer therapies, which focus on the incretin axis,
may carry a lower risk of hypoglycaemia. Their use, and more prudent use of older therapies with low risk of hypoglycaemia,
may help patients achieve improved glucose control for longer, and reduce the risk of diabetic complications.
Diabet. Med. 25, 245–254 (2008)
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Introduction
 
In healthy individuals, blood glucose concentrations are main-
tained within a very narrow range, despite major fluctuations
in glucose entry into the body and glucose utilization in tissue
metabolism. In people with diabetes mellitus, inadequate
insulin secretion results in high blood glucose concentrations.
The treatment of diabetes mellitus focuses on avoidance of
hyperglycaemia in order to avoid its associated symptoms and
to minimize the risk of vascular complications over time.
Treatments that elevate insulin concentrations in the blood
independent of the ambient glucose inevitably carry risk of
intermittent hypoglycaemia. Episodes of hypoglycaemia are
distressing, either because of the symptom response to the
falling blood glucose concentration, or because of the alteration
in brain function that occurs if the plasma glucose falls too low
to sustain normal neuronal function. Hypoglycaemia,
particularly when severe, is associated with considerable cost,
both to the individual and to the health service.
Most of the research into hypoglycaemia has used insulin-
induced hypoglycaemia as a tool and has looked at hypogly-
caemia in the insulin-deficient Type 1 diabetic population. The
occurrence of hypoglycaemia in the treatment of Type 2
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diabetes is also well recognized, but is more protean in nature,
having different risk factors and clinical features according to
the nature of the hypoglycaemic therapy, the extent of the
insulin secretory deficit and the duration of diabetes. With the
increasing drive for more strict glucose control in Type 2
diabetes and new therapies which may carry different risks for
hypoglycaemia from established therapies, a review of what is
known about hypoglycaemia in Type 2 diabetes is timely.
 
Search methodology
 
A Medline search for relevant papers between 1966 and
August 2006 was undertaken, using Web of Knowledge and
PubMed. A broad search strategy was used and main search
terms included: Type 2 diabetes, Type 2 diabetes mellitus,
Type 2 diabetic; hypoglycemia, hypoglycaemia, hypoglycemic,
hypoglycaemic; sulphonylurea, sulfonylurea, pioglitazone,
rosiglitazone, metformin, insulin; prevalence, incidence, cost,
fear of hypoglycemia/hypoglycaemia, health-related quality of
life, HRQoL, health-related utility, satisfaction, compliance/
adherence.
Main search terms were used in different combinations with
the terms from the issues to be addressed. Search terms were
truncated where necessary. In addition, we examined relevant
United Kingdom Prospective Diabetes Study (UKPDS) papers,
European Medicines Agency (EMEA), American Diabetes
Association (ADA) and Canadian Diabetes Association (CDA)
guidelines, references to papers of interest not identified via the
electronic search but retrieved in the reference columns of those
that were, and very recent references described at relevant meetings.
All papers concerning hypoglycaemia were considered eligible.
However, only the most pertinent papers which addressed the
issues of prevalence/incidence, cost of hypoglycaemia, fear of
hypoglycaemia, health-related quality of life (HRQoL) associated
with hypoglycaemia, satisfaction and compliance were included
in the final review. This limitation was set to ensure the most
relevant information to the topics were included.
Papers where the abstract had not been translated into
English were excluded, as were papers which did not pertain to
human adult populations with Type 2 diabetes. The initial
number of ‘hits’ from the search was 1946 papers. Papers that
were excluded totalled 1893 (not published in English, Type 1
diabetes, children, title of study deemed to be outside the scope
or not relevant to the scope of the review, other). Fifty-three
papers were therefore deemed eligible to best summarize or
present evidence. Additional references relating to hypoglycaemia in
patients with Type 2 diabetes were included if published after
August 2006 or providing supplementary information.
 
Definitions of hypoglycaemia
 
There is no consensus definition of hypoglycaemia in diabetes,
and a variety of criteria have been used to define hypoglycaemic
events. An early, very practical, definition of hypoglycaemia
was the presence of Whipple’s triad: decreased plasma glucose
concentration, symptoms compatible with hypoglycaemia and
rapid attenuation of those symptoms by correction of the low
glucose. With the recognition of hypoglycaemia occurring
without subjective awareness, this definition requires the
addition of ‘and signs’ to the ‘symptoms’ of item two, but
otherwise remains relevant to current practice. More recent
definitions have been provided by the ADA [1], the CDA [2]
and the EMEA [3]. These groups have attempted to define the
clinical severity of hypoglycaemia, classify the event according
to the presence or absence of a plasma glucose test and identify
a threshold level for plasma glucose at which hypoglycaemia is
diagnosed. Each group has defined a different level for this
threshold, ranging from 
 
<
 
 3.9 down to 
 
<
 
 3.0 mmol/l. This lack
of consensus makes it difficult to compare studies or quantify
the frequency of hypoglycaemia in Type 2 diabetes [4].
For the proper interpretation of published studies, a discussion
of the definition of the glucose threshold defining hypoglycaemia
is necessary. For a biochemical definition, surgeons, defining
spontaneous pathological hypoglycaemia requiring investigation
and treatment, and forensic pathologists have used glucose
concentrations of 
 
<
 
 2.2 mmol/l, to avoid defining healthy
people as hypoglycaemic [5,6]. At the other extreme, the
recent ADA consensus [1] has defined any glucose concentration
of 
 
<
 
 3.9 mmol/l as hypoglycaemia, based on the reduction in
endogenous insulin and increase in pancreatic glucagon which
can be demonstrated at this level. However, plasma glucose
can fall lower than this in health, especially in women. Further-
more, insulin-deficient patients with diabetes have lost the
ability to modulate either insulin or glucagon in response to
hypoglycaemia and depend instead on autonomic activation,
subjective awareness and adrenaline to defend against severe
hypoglycaemia [7]. Defining hypoglycaemia as any value
 
<
 
 3.9 mmol/l is likely to lead to overestimation of clinically
significant hypoglycaemia associated with any specific diabetes
therapy. The EMEA [3] recommend a value of 
 
<
 
 3.0 mmol/l to
define hypoglycaemia when assessing hypoglycaemic risk of
different treatment regimens. This has the virtue of robustly
detecting hypoglycaemia of clinical significance. Impaired
cognitive function is seen at plasma glucose concentrations of
 
<
 
 3.0 mmol/l [8,9], and avoidance of plasma glucose con-
centrations of 
 
<
 
 3.0 mmol/l has been able to restore hypogly-
caemia awareness to people with Type 1 diabetes and defective
counterregulation [10]. Avoidance of exposure to 
 
<
 
 3.0 mmol/l
is therefore clinically very desirable, whereas exposure to
glucose concentrations of 3.5–4.0 mmol/l, provided the glucose
fall is then arrested, is of little clinical significance. Because of
the clear activation of counterregulatory responses at arterialized
plasma glucose concentrations 
 
<
 
 3.5 mmol/l, this intermediate
number is also a reasonable definition of hypoglycaemia for
use in clinical practice. Parenthetically, hypoglycaemia as an
undesirable side effect of diabetes therapy should be distinguished
from the glucose concentration set as the lower limit to a
therapeutic target, which is correctly set higher (e.g. 4.0–
4.5 mmol/l), within the physiological range.
There is a degree of consensus when defining hypoglycaemia
by clinical picture alone. Most authorities [1–3] now accept
that severe hypoglycaemia is an episode in which the mental
state of a patient is so disturbed that they are unable to
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self-treat. The defining feature is the need for assistance from
another person, with subdivisions for cases where parenteral
therapy is required or coma or seizure occur. Mild hypoglycaemia
encompasses all other episodes, recognized by the patient and
self-treated. The category of moderate hypoglycaemia,
self-treated episodes involving significant disruption to
lifestyle, is now little used because of its imprecision and
subjective nature. It is important to recognize that people with
diabetes may refer to very symptomatic episodes of hypogly-
caemia as severe when from a medical perspective they are
justifiably mild, because the symptomatic patient self-treats
and avoids the morbidity of impaired conscious level.
The lack of consensus regarding definitions makes it
difficult to compare rates of hypoglycaemia across studies.
Clinically this is important, since treatment decisions may be
made on the evidence that one treatment is associated with less
hypoglycaemia than another. For the benefit of changing
therapies to be real, it is important to demonstrate that the
prevented hypoglycaemic events would have been clinically
problematic.
 
Risk factors for hypoglycaemia in Type 2 
diabetes
 
The most common cause of hypoglycaemia in Type 2 diabetes,
resulting in significant physical and psychosocial morbidity, is
iatrogenic, occurring with the use of insulin secretagogues and
insulin therapy [11]. These can overwhelm the normal
defences that should protect against a significant fall in plasma
glucose concentration, primarily by preventing a compen-
satory fall in circulating insulin. Risk of severe hypoglycaemia
is further increased by any defects in the other systems for
maintaining glucose concentrations.
Defects in glucagon responses to hypoglycaemia develop in
Type 2 diabetes [12], and some patients develop defects in the
other stress responses. Specific therapies may worsen these
defects; for example, sulphonylurea (SU) therapy sustains
intra-pancreatic insulin levels during hypoglycaemia, which
may further impair glucagon responses [13].
Risk factors for individual episodes of hypoglycaemia in
patients with Type 2 diabetes include behavioural, physiological
and therapeutic factors (see Table 1) [11,14–16]. The most
common behavioural factor which precipitates individual
episodes of severe hypoglycaemia that has been identified is
missed or irregular meals [17,18]. Other lifestyle factors
include alcohol, exercise and incorrect use of glucose-lowering
medication (dose/timing) [11].
Therapeutic/physiological factors associated with increased
risk include older age, duration of diabetes, presence of
comorbidities, renal impairment, loss of residual insulin secretion,
defective counterregulation and loss of awareness of hypogly-
caemia [7,12,19–23]. Use of other medications can also increase
risk. Some of these factors are interrelated, as increasing
diabetes duration is inevitably associated with increasing age
and increasing loss of endogenous insulin secretion.
Patient age also affects subjective awareness of hypoglycaemia.
In the elderly, neuroglycopenic symptoms specifically related
to articulation and coordination, which include unsteadiness,
blurred or double vision, lack of coordination and slurred
speech, are more common [24]. There are experimental data to
show that symptoms of hypoglycaemia decline with increasing
age, whereas the tendency for cognitive dysfunction in
hypoglycaemia increases [25].
Time of day is also important—even in the absence of
pharmacological therapy, the lowest plasma glucose of the day
is just before the evening meal and unsuspected hypoglycaemia
can occur at this time once drug therapy is started [26,27].
Intensification of treatment targets has also increased
frequency of severe hypoglycaemia, although this effect will
depend on the nature of the treatment used and the degree of
insulin deficiency in the patient [21].
Epidemiological data suggest that the incidence of hypo-
glycaemia in patients with Type 2 diabetes is highest when
patients are using insulin [21]. However, this risk is strongly
influenced by the clinical status of the patient. In the UKPDS,
rates of severe hypoglycaemia rose once known diabetes
duration exceeded 9 years (see Fig. 1).
 
The size of the problem
 
Data on frequency of hypoglycaemia must be interpreted with
caution for a number of reasons, including lack of consistency
in definition, changes in conventions of care over time, and the
duration of diabetes and degree of insulin deficiency. Data
may be skewed, since some patients experience very little
hypoglycaemia whereas others experience numerous episodes.
Table 1 Factors that may increase risk of hypoglycaemia during diabetes 
therapy
Impaired drug clearance
e.g. renal impairment, hepatic failure, hypothyroidism
Impaired counterregulatory capacity
e.g. Addison’s disease, growth hormone deficiency, 
hypopituitarism
Increased peripheral glucose uptake
e.g. exercise
Decreased endogenous glucose production
e.g. liver failure, alcohol
Impaired glucose absorption
e.g. malabsorption, anorexia
Concurrent medications
Decreased renal excretion of SUs
e.g. aspirin, allopurinol
Displacement of SUs from albumin
e.g. aspirin, warfarin, sulphonamides, trimethoprim, 
fibrates
Decreased metabolism of SUs
e.g. warfarin, mono-amine oxidase inhibitors
Insulin secretagogue activity
e.g. non-steroidal anti-inflammatory agents
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Rates of events and numbers of patients affected may give
different results.
Differences in the methods of data collection are also import-
ant. Although patient report is commonly used, inaccuracy of
recall is well documented [28]. Using patient databases may
underestimate the rate of hypoglycaemia, since few patients
report hypoglycaemia to their doctor. In one study, only 15%
of patients who experienced a mild/moderate event reported
the incident to their doctor at the next scheduled visit. Only
2.5% of patients experiencing a severe episode reported
additional visits to their general practitioner (GP) or hospital
specialist after the episode [29]. On a speculative note, some
patients may not admit hypoglycaemic events to physicians for
fear of appearing unable to manage their condition.
 
Insulin sensitizers (metformin and peroxisome 
proliferator-activated receptor gamma-agonists)
 
In patients on lifestyle adjustment and/or insulin sensitizing
treatments, the risk for hypoglycaemia is negligible. UKPDS
73 [30] showed rates (based on patient report) of 0.1% and
0.3% for lifestyle and metformin, respectively, in patients
receiving monotherapy or diet for 6 years from diagnosis. The
recent ADOPT study has reported rates of around 10% on
insulin sensitizers (metformin or rosiglitazone) over the
5 years of treatment, all self-reported [31]. Severe episodes
were reported in very few patients (0.1%) on either treatment.
Patients are more at risk of hypoglycaemia when the insulin
sensitizer is combined with insulin or insulin secretagogues.
For example, the recent PROactive trial, comparing the
addition of the peroxisome proliferator-activated receptor
gamma (PPAR
 
γ
 
)-agonist pioglitazone or placebo with usual
diabetic treatment in Type 2 patients at high risk of vascular
disease, found that the incidence of hypoglycaemia was signific-
antly higher in the pioglitazone plus usual treatment group
(28% vs. 20%, 
 
P
 
 
 
<
 
 0.001), although the incidence of severe
hypoglycaemia (defined as hypoglycaemia which resulted in
admission to hospital) was not significantly different (0.7% vs.
0.4%, 
 
P
 
 
 
=
 
 0.14). In the study, usual treatment included
metformin, SU and insulin, either individually or in combina-
tions and the data were not broken down by therapeutic
agent [32]. Parenthetically, hypoglycaemia with 
 
α
 
-glucosidase
inhibitors is not a major risk [33].
 
Sulphonylureas and insulin secretagogues
 
In the UKPDS, in the first year, 31% of patients treated with
glibenclamide experienced mild hypoglycaemic symptoms
[34]. Over the first 10 years, hypoglycaemia was reported by a
mean of 18% of patients treated with glibenclamide per year
[21].
A recent study commissioned by the Department for
Transport used formalized self reporting and continuous
glucose monitoring to compare rates (proportion of patients
experiencing an event) of hypoglycaemia prospectively over
9–12 months between patients with Type 2 diabetes treated
with SU, patients with Type 2 diabetes treated with insulin for
 
<
 
 2 years and those treated for 
 
>
 
 5 years, as well as patients
with Type 1 diabetes diagnosed within the last 5 years and
those with long duration (
 
>
 
 15 years) of Type 1 diabetes (see
next section for insulin data) [35]. Self-reported rates of mild
and severe (any episode requiring third-party help) hypogly-
caemia were 39% and 7%, respectively, in patients with Type
2 diabetes on SU. Rates of hypoglycaemia defined by values of
 
<
 
 2.2 mmol/l for at least 20 min on continuous glucose monitoring
were 14% in patients with Type 2 diabetes on SUs [35].
Conflicting data exist with regard to severe hypoglycaemic
events. Data derived from the Diabetes Audit and Research in
Tayside Scotland/Medicines Monitoring Unit Collaboration
(DARTS-MEMO) databases have revealed an annual rate of
severe events [defined as requiring emergency treatment from
Primary Care, ambulance, and Accident and Emergency
(A&E) or hospital services, with blood glucose 
 
<
 
 3.5 mmol/l
associated with the need for treatment] of 0.8% (or 0.9 events
per 100 patient-years) [22]. Older studies provide incidence
rates of 0.75 per 100 person-years (short-acting agents up to
0.24 per 100  person-years) [36] and 1.23 per 100  person-
years [19].
Data derived from the UK General Practice Research Database
(719 GP practices, 34 052 patient-years of SU therapy) have
reported that in users of SU, the annual risk of having one
recorded diagnosis of any hypoglycaemic event is 1.8%, rising
to 2.0% in those aged 
 
>
 
 65 years. The risk of SU was greatest
for glibenclamide: the study reported 25% fewer recorded
episodes for gliclazide and 40% fewer for glipizide compared
with glibenclamide [20]. These data should be interpreted with
FIGURE 1 The effect of duration of diabetes on the proportion of patients 
experiencing severe hypoglycaemic episodes. The open circles represent 
patients in the intensive arm in the United Kingdom Prospective Diabetes 
Study (UKPDS) and show an increase in the proportion of patients 
experiencing a severe hypoglycaemic event over time. In contrast the 
closed circles represent patients in the diet-only arm of UKPDS and do 
not show an increase [21]. Reprinted from The Lancet, 352: UKPDS 33. 
Intensive blood-glucose control with sulphonylureas or insulin compared 
with conventional treatment and risk of complications in patients with 
type 2 diabetes, 837–853, Copyright 1998, with permission from 
Elsevier.
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caution, since few patients report hypoglycaemia to their GP
[29]. Recorded diagnoses were used to calculate rates of
hypoglycaemia, and the study disregarded multiple diagnoses
of hypoglycaemia in the notes. However, these potential
quantitative problems should have existed equally for all
therapies [20].
Hypoglycaemia rates with the third-generation SUs (e.g.
glimepiride, glipizide and gliclazide) and the metiglinides (e.g.
repaglinide and nateglinide) appear to be lower than those
with glibenclamide and chlorpropamide. This is thought to be
partly related to duration of action [36], but there may be
other contributory factors. There is some evidence for
differential effects on insulin sensitivity, for example [37].
A prospective population-based study carried out in Germany
has found that rates of severe hypoglycaemia (defined as a
requirement for glucose or glucagon injection and blood
glucose 
 
<
 
 2.8 mmol/l) with glimepiride were significantly lower
than with glibenclamide at 0.86 per 1000 person-years vs. 5.6
per 1000 person-years [38]. Some severe hypoglycaemia occurred
with both agents, and the patients involved were elderly
(mean age 84  years), had very tight glycaemic control and
 
>
 
 60% had impaired renal function, irrespective of drug used.
A later study of episodes of severe hypoglycaemia on either
drug has failed to show any differences between the clinical
course and revealed that severe events were present at all
doses in both agents [39].
Pooled data from double-blind active-comparator studies
comparing repaglinide with SU have shown that the risks of
severe hypoglycaemia (defined as symptomatic hypoglycaemia
requiring help from another person plus blood glucose
 
<
 
 2.5 mmol/l) were 1.3% and 3.3%, respectively. Unfortunately,
the type of SU was not specified in the study [40]. A small study
of 3 months’ duration, which included 29 patients receiving
repaglinide alone and 27 receiving both repaglinide and
metformin, reported no severe hypoglycaemic events [41].
Although rates of hypoglycaemia with SU are relatively low,
particularly with the newer agents, around 636 000 patients
with Type 2 diabetes in the UK receive SU, either alone or as
part of combination therapy [42]. This equates, even at rates
of 0.8% per annum for severe events requiring emergency
assistance [22], to 
 
>
 
 5000 patients experiencing a severe event
each year.
 
Insulin
 
Rates of hypoglycaemia with insulin vary according to the
regimen and the stage of evolution of the person’s diabetes. In
the UKPDS, patients who were newly diagnosed at the start of
the study and randomized to insulin therapy reported ‘any’
hypoglycaemia rates of around 33% at year 1 and around
43% at year 10 [21]. Corresponding rates for severe episodes
(defined as episodes requiring third-party help or medical
intervention) were approximately 1.2% and 2.2%, respectively.
Data derived from the DARTS-MEMO databases have revealed
that 7.3% of patients with Type 2 diabetes treated with insulin
suffered at least one episode of severe hypoglycaemia—a
comparable figure to patients with Type 1 diabetes treated
with insulin (7.1%) [22].
One possible contributor to the difference in observed rate
of severe hypoglycaemia between the patient populations of
the UKPDS and DARTS-MEMO studies is duration of
diabetes—patients were newly diagnosed at entry to UKPDS
[21]. It is important also to look at the duration of insulin therapy
when considering hypoglycaemia rates in patients with Type 2
diabetes treated with insulin. The Department for Transport
study outlined above [35] found that 51% of patients taking
insulin for 
 
<
 
 2 years had experienced at least one hypoglycaemic
episode during the 9–12 months of follow-up, compared with
64% of patients taking insulin for 
 
>
 
 5 years. Rates of hypogly-
caemia recorded by continuous glucose monitoring (defined as
values of 
 
<
 
  2.2  mmol/l for at least 20 min) were 20% and
22%, respectively. However, corresponding figures for severe
hypoglycaemia were 7% and 25%. In comparison, the rate of
severe hypoglycaemia in insulin-treated Type 1 patients of
 
<
 
 5 years’ duration was 22%, rising to 46% in patients with
long duration (
 
>
 
 15 years) (Fig. 2).
The increase in severe episodes with duration of treatment
has been confirmed by a UK-based retrospective study of 215
insulin-treated patients with Type 2 diabetes, which revealed
that 15% had experienced severe hypoglycaemia in the preceding
year (60 episodes in 32 people) [23]. In this study, 29 (13%)
patients had been on insulin therapy for 
 
>
 
 10 years, with an
annual prevalence of severe hypoglycaemia of 31%.
However, insulin regimen is critical. To be included in the
Department for Transport study [35], patients had to be on at
least twice-daily insulin injections. Rates of symptomatic
hypoglycaemia in Type 2 patients started on bedtime
FIGURE 2 Proportion of patients with Type 2 and Type 1 diabetes of 
differing durations and receiving different regimens experiencing at least 
one severe hypoglycaemic attack during 9–12 months’ follow-up. 
All patients were receiving insulin except the group treated with 
sulphonylurea [35]. Reproduced from [35] with kind permission of 
Springer Science and Business Media.
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replacement of basal insulin using NPH insulin with metformin
are approximately half those of patients using twice-daily
insulin, despite larger insulin doses and lower HbA
 
1c
 
 [43].
Severe hypoglycaemia did not occur in that study and was also
absent from a later study of bedtime insulin and metformin
using either NPH or a peakless insulin analogue [44]. Indeed,
hypoglycaemia rates are no different in the early studies with
bedtime NPH [43,45] and the trials of best start regimens with
bedtime peakless analogue [46]. Hypoglycaemia rates are
slightly higher when SUs are retained in the oral regimen, and
best results seem to occur when these are replaced by using
slightly higher starting doses of the basal insulin.
Despite these reassuring data, professional fear of hypogly-
caemia often delays initiation of insulin therapy in Type 2
patients with suboptimal control on maximal oral therapy, to
the detriment of glycaemic control and patient care [47].
 
Incretin enhancement therapies: incretin analogues and 
dipeptidyl-peptidase 4 inhibitors
 
Newly emerging therapies based around enhancement of
incretin action result in improved glycaemic control through a
variety of mechanisms. The incretin, glucagon-like peptide
(GLP)-1, released from the small intestine after eating, enhances
insulin responses to glucose, as well as suppressing glucagon
postprandially. It is too early to assess accurately the hypoglycaemic
risk profile of such agents, although the glucose-lowering
effect of GLP-1 appears to be glucose dependent [48].
Early clinical trials with the GLP-1 analogue exenatide, and
the dipeptidyl-peptidase 4 inhibitors (such as sitagliptin and
vildagliptin, which elevate endogenous GLP-1 concentrations
by preventing its breakdown) do not seem to be associated
with increased risk of hypoglycaemia when used as monotherapy
[49] or in combination with insulin sensitizers (metformin and
PPAR
 
γ
 
-agonists) [50–54] in short-term clinical studies of
between 24 and 52 weeks, although studies with exanatide
have demonstrated increased risk of hypoglycaemia if used in
association with SUs [55,56]. In a 30-week trial of exenatide
vs. placebo in addition to treatment with SU [55], rates of mild/
moderate hypoglycaemia were 3% (4/123) in the placebo
group compared with 14% (18/125) in the exenatide 5 
 
μ
 
g
twice daily group, with no serious events in either arm. A
further 30-week trial comparing exenatide and placebo and in
addition to maximum dose combination therapy with SU and
metformin, has revealed rates of mild/moderate hypoglycaemia
of 13% (31/247) in the placebo group and 19% (47/245) in the
exenatide 5 
 
μ
 
g twice daily group [56].
The authors of both papers have suggested that the increased
hypoglycaemia seen in the exanatide plus SU arms was a result
of achieving lower levels of glycaemia coupled with the
background hypoglycaemic risk associated with SU therapy
[21,55,56].
The data with the incretin enhancement therapies thus
suggests that the risk of hypoglycaemia is determined by the
nature of the other glucose-lowering therapies used with them.
 
The consequences of hypoglycaemia
 
Clinical consequences
 
Mild symptomatic hypoglycaemia is not reported to have any
serious clinical effects, apart from the potential for inducing
defects in counterregulatory responses and impaired awareness
to subsequent hypoglycaemia. Nevertheless, people with
diabetes are fearful of hypoglycaemia (see below), and even
clinically trivial events may be enough to inhibit concordance
with therapy.
Severe hypoglycaemia is more serious, particularly in the
elderly. In a prospective study of people aged 
 
>
 
 80 years, with
well-controlled (mean HbA
 
1c
 
 5.1%) Type 2 diabetes, 25% of
hospital admissions associated with diabetes were due to
severe hypoglycaemia (defined as symptomatic event requiring
third-party treatment and blood glucose 
 
<
 
 2.8 mmol/l) [57].
Patients had considerable comorbidity (cardiovascular disease,
dementia or diabetic complications).
In a retrospective cohort study of elderly patients (mean age
78 years) presenting to A&E departments in Tennessee with
hypoglycaemia (defined as hospitalisation, A&E admission or
death associated with hypoglycaemic symptoms and a blood
glucose of 
 
<
 
 2.8 mmol/l), almost all patients presented with
neuroglycopenic symptoms and 49% presented with loss of
consciousness. Approximately 5% were associated with stroke,
myocardial infarction, transient ischaemic attack, injury or death,
although the cause-and-effect relationship is not clear [19].
Severe hypoglycaemia is also associated with increased
mortality. For example, in cases of severe hypoglycaemia
induced by SU monotherapy, the overall mortality rate has
been estimated as approximately 9% [58]. Deficits in cognitive
functioning have been found to occur during hypoglycaemic
events [8,9], and in one study over one-fifth of patients with
Type 2 diabetes were found unconscious during a severe
hypoglycaemic episode [29].
A retrospective review of 102 patients (90% with Type 2
diabetes) admitted to hospital with drug-induced hypoglycaemic
coma revealed a mortality rate of 4.9% (
 
n
 
 
 
=
 
 5) (all in patients
with Type 2 diabetes) [16]. However, it was not possible to
confirm whether the deaths were due to hypoglycaemia, since
all five patients had serious comorbidities. Coma was
associated with considerable morbidity, including head
trauma, fracture, seizures, transient asymptomatic myocardial
ischaemia and stroke.
In the UK, there are five fatal road traffic accidents each year
and 45 serious events each month as a result of hypoglycaemia.
Although the data do not differentiate between hypoglycaemia
due to Type 1 or Type 2 diabetes, it is likely that a proportion of
these incidents will involve patients with Type 2 diabetes [59].
Hypoglycaemia in people with Type 2 diabetes has a
detrimental impact on HRQoL. This impact is apparent across
different types of HRQoL measure. People who experienced
hypoglycaemic symptoms had a lower mean health-related
utility (HRU), as measured by the EQ-5D, compared with
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those who did not experience symptoms (0.70 vs. 0.77,
 
P
 
 
 
=
 
 0.006) [60]. People with Type 2 diabetes have lower HRU
as measured by EQ-5D than those with Type 1 diabetes [61].
Severity of the hypoglycaemia correlates with HRU, those
with severe hypoglycaemia having the lowest HRU and
HRQoL across all dimensions of the SF-36 except vitality [61].
The UKPDS has reported that Type 2 patients who experience
more than two hypoglycaemic events during the study report
more mood disturbance (problems with fatigue, tension,
depression and anger) than those who do not report any events
[62], and patients who experience these events report more
generalized worries with their life and with their diabetes
control than those not experiencing symptoms [60].
 
Cost implications
 
The utilization of healthcare resources and treatment costs of
hypoglycaemia in Type 2 diabetes varies according to country,
and estimates will be affected by factors such as the prevalence
of hypoglycaemia; classifications of hypoglycaemic events;
patient characteristics, knowledge and attitudes to hypoglycaemic
events; and varying quality and implementation of care across
different healthcare systems.
Estimates vary for the amount of healthcare resources used
by patients after a hypoglycaemic event, and these resources
are almost certainly both underestimated and underutilized, as
many patients will self treat an event and not mention the
experience to their physician [29]. In one UK study, the mean
numbers of primary care healthcare resources (visits to the
nurse or physician) per patient with Type 2 diabetes in a
6-week period for mild/moderate and severe hypoglycaemia
were reported as 11.5 and 13.2, respectively. To place this in
a financial context, costs at these rates over a 6-week period
for mild/moderate hypoglycaemia range from £287.50 if all
consultations are with a GP to £92 if all consultations are with
the Practice Nurse. Corresponding figures are £330 and £105.60
for severe hypoglycaemia [61,63]. However, a Canadian study
has found that after mild/moderate and severe events, 84.5%
and 83.1%, respectively, of the patients surveyed self-treated
their hypoglycaemic event. Only 3.4% of those who reported
a severe event requested an ambulance and only 5.5% had an
A&E or hospital visit [29].
Scottish data based on documented resource use during
1 year show 7.3% of insulin-treated and 0.8% of SU-treated
patients involved emergency services in a severe hypoglycaemic
event, with 
 
>
 
 80% of those events requiring an ambulance and
66% requiring Primary Care services or A&E. They estimated
the annual direct cost of treating severe hypoglycaemia in
excess of £13 million pounds for all patients with diabetes in
the UK. Of the 244 episodes reported in the study, 57% were
in patients with Type 2 diabetes. Therefore, we can estimate
the cost of hypoglycaemia due to Type 2 diabetes at around
£7.4 million [22]. The study included cost of ambulance, A&E
departments and ward use at £127, £89 and £218 per day,
respectively, but did not estimate the associated costs of
any injury, disability or work loss associated with the acute
event.
There is evidence to suggest that people with Type 2 diabetes
lose on average 3 productive days (days lost from paid
employment, non-paid normal activities and days requiring
help with usual activities) following a severe hypoglycaemic
attack [61]. In one study, over a 6-week period severe hypogly-
caemia resulted in the loss of a mean of 8.6 productive days per
patient with Type 2 diabetes [61].
Hospital admission due to hypoglycaemia in patients with
Type 2 diabetes is associated with poor general condition after
the event, concomitant illness and injuries sustained during the
event [64]. A German study has estimated that costs for
hypoglycaemia in Type 2 diabetes are substantially higher
than in Type 1 patients, ($8000 compared with $44 300
dollars), reflecting longer length of hospital stay associated
with older age, comorbidity and polypharmacy [64].
Data derived from the DARTS-MEMO databases reveal
that 28% of episodes of severe hypoglycaemia (which were
bad enough to merit involvement of emergency services)
resulted in hospital admission [22]. The mean length of
hospital stay was 4.4 days, which at a cost of £218 per day
equates to £959 per hospitalisation for severe hypoglycaemia.
Other studies have reported the mean length of hospital stay
associated with severe hypoglycaemia at between 6.6 and
9.5 days [64,65], with mean hypoglycaemic event duration
reported between 12 and 72 h [16]. It should be noted that the
rate of hospital admission may be affected by management
protocols as well as individual medical need, as protocols for
severe hypoglycaemia induced by SU therapy mandate admission
to observe for recurrence of the hypoglycaemia, but such
admissions, if uncomplicated, should be relatively short.
 
Fear of hypoglycaemia and hypoglycaemia as a barrier to 
glycaemic control
 
Hypoglycaemia is clearly an important limiting factor in the
glycaemic management of patients with diabetes and a
significant barrier in terms of adherence to medication and
achievement of the life-long goal to attain normoglycaemia [66].
Fear of hypoglycaemia is an additional psychological burden
that patients with Type 2 diabetes experience [66]. A study that
used the Hypoglycaemic Fear Survey, which combines a worry
and behavioural scale [67], found that Type 2 diabetic patients
reported increased fear of hypoglycaemia as the number of both
mild/moderate and severe events increased. Women reported
significantly more fear of hypoglycaemia than men [68].
It is suggested that the presence (or fear) of hypoglycaemia
can limit the aggressiveness of drug therapy to achieve reduction
of micro- and macrovascular complications, decrease adherence
to diet and reduce patients’ willingness to take medications as
directed [29,69]. The perceived risk of hypoglycaemia with
insulin therapy has led to restrictions in licensing for driving.
Intensive therapy, designed to minimize the risk of
long-term diabetic complications, has been associated
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with increased risk of severe hypoglycaemia, and fear of
hypoglycaemia with a barrier to achieving and main-
taining near-normoglycaemia. In one study, people with
Type 2 diabetes with HbA
 
1c
 
 
 
<
 
 8.0% at baseline receiving a
glibenclamide-containing regimen were up to 4.8 times
more  likely to experience hypoglycaemia than those with
HbA
 
1c
 
 
 
>
 
 8.0% [70]. In the UKPDS [21] and a US Veterans
Affairs  study [71], those in the intensive therapy group
reported significantly more hypoglycaemia than those on
conventional therapy.
Hypoglycaemia has also been suggested as a private experience
that is rarely discussed with healthcare providers [72], which
may burden the patient more than physicians are aware. Sadly,
patients reported to a UK survey that they received very little
information and guidance from physicians regarding adverse
effects of their glucose-lowering regimens. Only 5% of 165
patients with Type 2 diabetes were able to give the correct
answers to questions regarding the adverse effects of SUs, and
only 10% of people treated with a SU knew that it could cause
hypoglycaemia [73].
Studies indicate that patients may balance their glucose
levels against the risk of a hypoglycaemic event, with some
choosing to keep their blood glucose higher than recommended
to avoid hypoglycaemia [29]. Such patients may sacrifice the
long-term benefits of reducing micro- and macrovascular
complications [66]. With growing evidence that macrovascular
disease may require lower mean glycaemia than that required
for microvascular disease, the limitation of hypoglycaemia
associated with current therapies may become more problematic,
inhibiting patients’ ability to lower mean glucose concentra-
tions sufficiently or long enough to impact on macrovascular
end-points as required [74,75].
 
Conclusions
 
Glucose-lowering therapies that are associated with hyper-
insulinaemia that is not glucose dependent, such as the SUs and
insulin, carry a risk for hypoglycaemia that is increased in
older patients, those with longer duration of diabetes, lesser
insulin reserve and other comorbidities, including renal
impairment, hypothyroidism and defects of counterregulatory
hormone secretion. The risk may be greater in the drive for
intensified therapy and strict glycaemic control.
Severe hypoglycaemia also increases with increasing
duration of Type 2 diabetes, and of insulin therapy, presumably
as a result of increasing deficiency of endogenous, glucose-
regulated insulin secretion, with rates of self-reported severe
hypoglycaemia rising from 7 to 25% in those who have been
taking insulin for 
 
>
 
 5 years.
Although the rates of severe hypoglycaemia are lower in
patients taking SUs, especially the newer third-generation
agents, there are large numbers of patients taking these drugs
in the UK, either alone or as part of combination therapy. Even
at rates of 0.8% per annum for severe events requiring
emergency care, this equates to 
 
>
 
 5000 patients each year.
Hypoglycaemia has a substantial clinical impact in terms of
mortality, morbidity and quality of life. The cost implications
of severe episodes, both direct hospital costs and indirect costs
due to inability to work, are considerable. Perhaps more
important, hypoglycaemia and fear of hypoglycaemia limit the
ability of current diabetes medications to achieve and sustain
the degree of glycaemic control predicted to prevent the
increased risk of diabetic complications.
Newer therapies which may carry a lower risk of hypogly-
caemia, and more prudent use of older ones, may help patients
achieve improved glucose control, defined in terms of both low
HbA
 
1c
 
 and low risk of significant hypoglycaemia, for longer,
and reduce the risk of diabetic complications.
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